{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T13:43:00Z","timestamp":1794750180577,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pevonedistat (TAK924) is a Nedd8-activating enzyme inhibitor with preclinical activity in non-Hodgkin lymphoma (NHL). This open-label, Phase I, multicenter, investigator-sponsored study enrolled patients with relapsed\/refractory (R\/R) NHL and chronic lymphocytic leukemia (CLL). The primary objective was safety. Pevonedistat was given intravenously on days 1, 3, 5 of a 21-day cycle for 8 cycles at five dose levels (15 to 50\u2009mg\/m<jats:sup>2<\/jats:sup>); ibrutinib was administered at 420 or 560\u2009mg orally daily continuously. Eighteen patients with NHL were enrolled, including 8 patients with mantle cell lymphoma (MCL) and 4 patients with CLL. One dose-limiting toxicity (mediastinal hemorrhage) occurred at 50\u2009mg\/m<jats:sup>2<\/jats:sup> of pevonedistat which is the estimated maximum tolerated dose. Bruising and diarrhea were the most common adverse events (56% and 44%). Atrial fibrillation occurred in 3 patients (17%). Grade \u22653 toxicities included arthralgia, atrial fibrillation, bone pain, diarrhea, hypertension, and mediastinal hemorrhage (one patient each). The overall response rate (ORR) was 65% (100% ORR in MCL). Pevonedistat disposition was not modified by ibrutinib. scRNA-Seq analysis showed that pevonedistat downregulated NF\u03baB signaling in malignant B-cells in vivo. Thus, pevonedistat combined with ibrutinib demonstrated safety and promising early efficacy in NHL and CLL. NAE inhibition downregulated NF\u03baB signaling in vivo.<\/jats:p>","DOI":"10.1038\/s41408-022-00763-w","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T06:02:54Z","timestamp":1673416974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma"],"prefix":"10.1038","volume":"13","author":[{"given":"Pallawi","family":"Torka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha Kambhampati","family":"Thiruvengadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Vuong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanjun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3346-8892","authenticated-orcid":false,"given":"Alexandra","family":"Muir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Orand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Borja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lynne Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E. F.","family":"Spurgeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel D.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3364-8324","authenticated-orcid":false,"given":"Zheng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"763_CR1","first-page":"5","volume":"9","author":"KC Thandra","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, Padala SA, Barsouk A, Rawla P. Epidemiology of non-hodgkin\u2019s lymphoma. Med Sci (Basel). 2021;9:5.","journal-title":"Med Sci (Basel)"},{"key":"763_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3960\/jslrt.56.79","volume":"56","author":"K Miyazaki","year":"2016","unstructured":"Miyazaki K. Treatment of diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56:79\u201388.","journal-title":"J Clin Exp Hematop"},{"key":"763_CR3","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009;458:732\u20136.","journal-title":"Nature"},{"key":"763_CR4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1182\/blood-2010-03-272567","volume":"116","author":"MA Milhollen","year":"2010","unstructured":"Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 2010;116:1515\u201323.","journal-title":"Blood"},{"key":"763_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/jha2.2","volume":"1","author":"P Torka","year":"2020","unstructured":"Torka P, Mavis C, Kothari S, Belliotti S, Gu J, Sundaram S, et al. Pevonedistat, a NEDD8-activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre-clinical models of diffuse large B-cell lymphoma. EJHaem. 2020;1:122\u201332.","journal-title":"EJHaem"},{"key":"763_CR6","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-13-0987","volume":"20","author":"JC Godbersen","year":"2014","unstructured":"Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-kappaB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014;20:1576\u201389.","journal-title":"Clin Cancer Res"},{"key":"763_CR7","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3324\/haematol.2017.170571","volume":"102","author":"C Paiva","year":"2017","unstructured":"Paiva C, Rowland TA, Sreekantham B, Godbersen C, Best SR, Kaur P, et al. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia. Haematologica. 2017;102:1890\u2013900.","journal-title":"Haematologica"},{"key":"763_CR8","doi-asserted-by":"publisher","first-page":"e1807","DOI":"10.1038\/cddis.2015.161","volume":"6","author":"C Paiva","year":"2015","unstructured":"Paiva C, Godbersen JC, Berger A, Brown JR, Danilov AV. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents. Cell Death Dis. 2015;6:e1807.","journal-title":"Cell Death Dis"},{"key":"763_CR9","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1182\/blood-2015-04-640920","volume":"127","author":"NM Czuczman","year":"2016","unstructured":"Czuczman NM, Barth MJ, Gu J, Neppalli V, Mavis C, Frys SE. et al. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo. Blood. 2016;127:1128\u201337.","journal-title":"Blood"},{"key":"763_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/1078-0432.CCR-15-1237","volume":"22","author":"JJ Shah","year":"2016","unstructured":"Shah JJ, Jakubowiak AJ, O\u2019Connor OA, Orlowski RZ, Harvey RD, Smith MR, et al. Phase I study of the novel investigational NEDD8-activating enzyme inhibitor pevonedistat (MLN4924) in patients with relapsed\/refractory multiple myeloma or lymphoma. Clin Cancer Res. 2016;22:34\u201343.","journal-title":"Clin Cancer Res"},{"key":"763_CR11","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","volume":"246","author":"KH Lim","year":"2012","unstructured":"Lim KH, Yang Y, Staudt LM. Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies. Immunological Rev. 2012;246:359\u201378.","journal-title":"Immunological Rev"},{"key":"763_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl J Med. 2013;369:507\u201316.","journal-title":"N. Engl J Med"},{"key":"763_CR13","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363.","journal-title":"Am J Hematol"},{"key":"763_CR14","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.2021014162","volume":"139","author":"Y Song","year":"2022","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022;139:3148\u201358.","journal-title":"Blood"},{"key":"763_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ajh.25436","volume":"94","author":"SM O\u2019Brien","year":"2019","unstructured":"O\u2019Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. Am J Hematol. 2019;94:554\u201362.","journal-title":"Am J Hematol"},{"key":"763_CR16","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1007\/s12325-022-02258-3","volume":"39","author":"S Rai","year":"2022","unstructured":"Rai S, Tanizawa Y, Cai Z, Huang YJ, Taipale K, Tajimi M. Outcomes for recurrent mantle cell lymphoma post-ibrutinib therapy: a retrospective cohort study from a Japanese Administrative Database. Adv Ther. 2022;39:4792\u2013807.","journal-title":"Adv Ther"},{"key":"763_CR17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1182\/blood-2017-09-805895","volume":"131","author":"RT Swords","year":"2018","unstructured":"Swords RT, Coutre S, Maris MB, Zeidner JF, Foran JM, Cruz J, et al. Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 2018;131:1415\u201324.","journal-title":"Blood"},{"key":"763_CR18","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","volume":"31","author":"Y Ji","year":"2013","unstructured":"Ji Y, Wang SJ. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31:1785\u201391.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"763_CR19","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"763_CR20","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"763_CR21","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2147\/DDDT.S136988","volume":"11","author":"RL Van Heertum","year":"2017","unstructured":"Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, et al. Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials. Drug Des Devel Ther. 2017;11:1719\u201328.","journal-title":"Drug Des Devel Ther"},{"key":"763_CR22","doi-asserted-by":"publisher","first-page":"e153283","DOI":"10.1172\/JCI153283","volume":"132","author":"S Yi","year":"2022","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022;132:e153283.","journal-title":"J Clin Invest"},{"key":"763_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.cell.2011.09.019","volume":"147","author":"MJ Emanuele","year":"2011","unstructured":"Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, et al. Global identification of modular cullin-RING ligase substrates. Cell. 2011;147:459\u201374.","journal-title":"Cell"},{"key":"763_CR24","doi-asserted-by":"publisher","first-page":"204062072198958","DOI":"10.1177\/2040620721989588","volume":"12","author":"MJ Gordon","year":"2021","unstructured":"Gordon MJ, Danilov AV. The evolving role of Bruton\u2019s tyrosine kinase inhibitors in chronic lymphocytic leukemia. Ther Adv Hematol. 2021;12:2040620721989588.","journal-title":"Ther Adv Hematol"},{"key":"763_CR25","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","volume":"126","author":"ML Wang","year":"2015","unstructured":"Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015;126:739\u201345.","journal-title":"Blood"},{"key":"763_CR26","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.21.00693","volume":"39","author":"H Abdel-Qadir","year":"2021","unstructured":"Abdel-Qadir H, Sabrie N, Leong D, Pang A, Austin PC, Prica A, et al. Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study. J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39:3453\u201362.","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"763_CR27","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao L, Salem JE, Clauss S, Hanley A, Bapat A, Hulsmans M, et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation. 2020;142:2443\u201355.","journal-title":"Circulation"},{"key":"763_CR28","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N. Engl J Med. 2018;378:1211\u201323.","journal-title":"N. Engl J Med"},{"key":"763_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood.2020008727","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood. 2021;137:877\u201387.","journal-title":"Blood"},{"key":"763_CR30","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1182\/blood.V126.23.3980.3980","volume":"126","author":"K Kolibaba","year":"2015","unstructured":"Kolibaba K, Burke JM, Brooks HD, Mahadevan D, Melear J, Farber CM, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and\/or refractory mantle cell lymphoma; results of a phase II trial. Blood. 2015;126:3980.","journal-title":"Blood"},{"key":"763_CR31","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","volume":"133","author":"P Martin","year":"2019","unstructured":"Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133:1201\u20134.","journal-title":"Blood"},{"key":"763_CR32","doi-asserted-by":"publisher","first-page":"e19043","DOI":"10.1200\/JCO.2019.37.15_suppl.e19043","volume":"37","author":"P Thirunagari","year":"2019","unstructured":"Thirunagari P, Siyahian A, Iftikhar A, Wahab A, Ashraf A, Majeed A, et al. The efficacy of ibrutinib-based combination therapy for mantle cell lymphoma: A systematic review. J Clin Oncol. 2019;37:e19043\u2013e.","journal-title":"J Clin Oncol"},{"key":"763_CR33","doi-asserted-by":"publisher","first-page":"TPS8613","DOI":"10.1200\/jco.2013.31.15_suppl.tps8613","volume":"31","author":"M Wang","year":"2013","unstructured":"Wang M, Gordon LI, Rule S, Goy A, Hermine O, Rizo A, et al. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL). J Clin Oncol. 2013;31:TPS8613\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"763_CR34","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","volume":"5","author":"M Jerkeman","year":"2018","unstructured":"Jerkeman M, Eskelund CW, Hutchings M, Raty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5:e109\u2013e16.","journal-title":"Lancet Haematol"},{"key":"763_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10637-018-0610-0","volume":"37","author":"AC Lockhart","year":"2019","unstructured":"Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, et al. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest N. Drugs. 2019;37:87\u201397.","journal-title":"Invest N. Drugs"},{"key":"763_CR36","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1078-0432.CCR-15-1338","volume":"22","author":"J Sarantopoulos","year":"2016","unstructured":"Sarantopoulos J, Shapiro GI, Cohen RB, Clark JW, Kauh JS, Weiss GJ, et al. Phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924\/MLN4924) in patients with advanced solid tumors. Clin Cancer Res. 2016;22:847\u201357.","journal-title":"Clin Cancer Res"},{"key":"763_CR37","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1111\/bcp.13915","volume":"85","author":"H Faessel","year":"2019","unstructured":"Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, et al. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. Br J Clin Pharm. 2019;85:1464\u201373.","journal-title":"Br J Clin Pharm"},{"key":"763_CR38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/bjh.13323","volume":"169","author":"RT Swords","year":"2015","unstructured":"Swords RT, Erba HP, DeAngelo DJ, Bixby DL, Altman JK, Maris M, et al. Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study. Br J Haematol. 2015;169:534\u201343.","journal-title":"Br J Haematol"},{"key":"763_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11899-021-00605-9","volume":"16","author":"E Nabrinsky","year":"2021","unstructured":"Nabrinsky E, Danilov AV, Koller PB. High-risk mantle cell lymphoma in the era of novel agents. Curr Hematol Malig Rep. 2021;16:8\u201318.","journal-title":"Curr Hematol Malig Rep"},{"key":"763_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95:623\u20139.","journal-title":"Am J Hematol"},{"key":"763_CR41","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1182\/blood.2020009578","volume":"138","author":"S Ma","year":"2021","unstructured":"Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, et al. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 2021;138:836\u201346.","journal-title":"Blood"},{"key":"763_CR42","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3109\/10428194.2014.990901","volume":"56","author":"JC Godbersen","year":"2015","unstructured":"Godbersen JC, Paiva C, Danilova OV, Berger A, Brown JR, Danilov AV. Targeting neddylation effectively antagonizes nuclear factor-kappaB in chronic lymphocytic leukemia B-cells. Leuk Lymphoma. 2015;56:1566\u20139.","journal-title":"Leuk Lymphoma"},{"key":"763_CR43","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41375-020-0794-0","volume":"35","author":"S Best","year":"2021","unstructured":"Best S, Lam V, Liu T, Bruss N, Kittai A, Danilova OV, et al. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells. Leukemia. 2021;35:156\u201368.","journal-title":"Leukemia"},{"key":"763_CR44","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.18632\/oncotarget.28019","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Best S, Danilov AV. Neddylation and anti-tumor immunity. Oncotarget. 2021;12:2227\u201330.","journal-title":"Oncotarget"},{"key":"763_CR45","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1182\/bloodadvances.2017006809","volume":"1","author":"K Maharaj","year":"2017","unstructured":"Maharaj K, Sahakian E, Pinilla-Ibarz J. Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. Blood Adv. 2017;1:1867\u201375.","journal-title":"Blood Adv"},{"key":"763_CR46","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long M, Beckwith K, Do P, Mundy BL, Gordon A, Lehman AM, et al. Ibrutinib treatment improves T cell number and function in CLL patients. The. J Clin Investig. 2017;127:3052\u201364.","journal-title":"J Clin Investig"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00763-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00763-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T09:03:22Z","timestamp":1725613402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00763-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["763"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00763-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AVD has received consulting fees from Abbvie, AstraZeneca, Bayer Oncology, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Lilly Oncology, Nurix, Oncovalent, Pharmacyclics and TG Therapeutics and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, Cyclacel, MEI Pharma, Nurix and Takeda Oncology. PT has received consulting fees from ADC Therapeutics, Genentech and TG Therapeutics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}